Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro laboratory study without human participants.
PubMed 25675519 · doi:10.1073/pnas.1424934112
What was done
Researchers examined glucagon secretion under hyperglycemic conditions without insulin in InR1-G9 alpha cells, perfused pancreata from insulin-deficient rats with type 1 diabetes (T1D), and T1D mice. They also tested the effect of mAb Ac, a glucagon receptor (GCGR) antagonizing antibody, on blood glucose and HbA1c levels in insulin-deficient T1D mice.
What was found
Raising glucose from 5 to 25 mM without insulin increased glucagon secretion ~two- to fivefold in InR1-G9 alpha cells and ~18-fold in perfused pancreata from T1D rats. Insulin-treated T1D mice had threefold higher plasma glucagon during hyperglycemic surges than during normoglycemic intervals. In insulin-deficient T1D mice, GCGR blockade with mAb Ac maintained blood glucose below 100 mg/dL and HbA1c below 4%.
Why it matters
The study demonstrates a mechanism where hyperglycemia directly stimulates hyperglucagonemia in the absence of acute insulin increases, suggesting glucagon receptor blockade as a potential insulin-independent target for managing type 1 diabetes.
Limits
Findings are entirely in rodent and cell models and may not translate to humans. The abstract does not report sample sizes, confidence intervals, treatment durations, or evaluation of potential adverse effects such as hypoglycemia or hepatic lipid accumulation.
Cited by
- supports Dr. Roger Unger published papers demonstrating that inhibiting glucagon excess in type 1 diabetes corrects hyperglycemia without requiring insulin administration.